Tel: 01789 267520

SMA UK, MDUK and TreatSMA send joint letters to NICE, Biogen and NHS England

30 November 2018

As an act of ‘good faith’ in their commitment to progress discussions to a satisfactory conclusion, we urge all three parties to agree, with immediate effect, to implement a ‘bridging solution’ for access to nusinersen for any infants with SMA Type 1.

Read the letter to Biogen

Read the letter to NICE

Read the letter to NHS England